Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jan, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(6 years from now) | |
US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(12 years from now) |
Xospata is owned by Astellas.
Xospata contains Gilteritinib Fumarate.
Xospata has a total of 3 drug patents out of which 0 drug patents have expired.
Xospata was authorised for market use on 28 November, 2018.
Xospata is available in tablet;oral dosage forms.
Xospata can be used as treatment of acute myeloid leukemia (aml).
Drug patent challenges can be filed against Xospata from 2022-11-28.
The generics of Xospata are possible to be released after 01 July, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic